Dr Taiyin Yang joins Board at Brii Biosciences

Brii Biosciences, with operations in the US and China, has announced the appointment of healthcare industry veteran Dr Taiyin Yang, to the company’s Board of Directors as co-chair of the newly expanded Audit and Risk Committee, effective September 1, 2022. Dr Taiyin Yang is the former Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences. She directed operations of process, device and formulation development, manufacturing, packaging, analytical operations, laboratory information systems and data science, to name a few. Under her leadership, Gilead developed the world’s first HIV single tablet regimen and advanced numerous compounds from early-stage development to market, reaching millions of people around the world. Prior to joining Gilead in 1993, she worked at Syntex Corporation for more than a decade, where she contributed to the development and commercialisation of more than 10 medicines.